PFCS
RLMD icon

Pale Fire Capital SE’s Relmada Therapeutics RLMD Stock Holding History

Pale Fire Capital SE’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219K Hold
31,650
– – 0.02% 64
2026
Q1 		$220K Sell
31,650
-12,900
-29% -$61K 0.02% 51
2025
Q4 		$215K Buy
+44,550
New +$149K 0.01% 48

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pale Fire Capital SE's RLMD Position: Q2 2026 in Review

Pale Fire Capital SE held its Relmada Therapeutics (RLMD) position steady in Q2 2026 at 31,650 shares worth $219K. The position accounts for 0.02% of the portfolio, ranked #64.

Pale Fire Capital SE first reported a position in RLMD in Q4 2025 and has held it in 3 quarters since. The position peaked at $220K in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Pale Fire Capital SE held 31,650 shares of Relmada Therapeutics worth $219K as of Q2 2026.
  • Pale Fire Capital SE left its Relmada Therapeutics share count unchanged in Q2 2026.
  • Relmada Therapeutics made up 0.02% of Pale Fire Capital SE's portfolio in Q2 2026, its #64 holding.
  • Pale Fire Capital SE first reported a position in Relmada Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Pale Fire Capital SE's Relmada Therapeutics position peaked at $220K in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Pale Fire Capital SE's 13F filing for Q2 2026, filed 13 Aug 2026.